Benjamin Harshbarger - 23 Jan 2026 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role: Chief Legal Officer
Signature: /s/ Ben Harshbarger
Issuer symbol: ATXS
Transactions as of: 23 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 23 Jan 2026, 16:25:42 UTC
Previous filing: 25 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Harshbarger Benjamin	Chief Legal Officer	C/O ASTRIA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 10TH FLOOR, BOSTON	/s/ Ben Harshbarger	23 Jan 2026	0001653133

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATXS	Stock Option (Right to Buy)	Disposed to Issuer	-33,333	-100%	23 Jan 2026	Common Stock	33,333	$12.96	Direct	F1, F2
transaction	ATXS	Stock Option (Right to Buy)	Disposed to Issuer	-55,000	-100%	23 Jan 2026	Common Stock	55,000	$6.51	Direct	F2
transaction	ATXS	Stock Option (Right to Buy)	Disposed to Issuer	-262,500	-100%	23 Jan 2026	Common Stock	262,500	$6.41	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Benjamin Harshbarger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
F2	Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

Content

These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

Remarks:

At the Effective Time, each Issuer stock option for which the applicable exercise price was equal to or greater than $13.00 (each, an "Out-of-the-Money Option") that was outstanding immediately prior to the Effective Time was canceled for no consideration, which cancelation is exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-4(d) and Rule 16b-6(d) thereunder. Accordingly, the Reporting Person's Out-of-the-Money Options that were canceled in the Merger are not reported herein.